Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy Rodríguez Sevilla, Juan José Sáinz Pérez, Juan Several clinical risk models have been proposed to predict the outcome of follicular lymphoma (FL). The development of next-generation sequencing technologies has allowed the integration of somatic gene mutations into clinical scores to build genotyped-based risk models, such as the m7–Follicular Lymphoma International Prognostic Index (FLIPI). We explored 4 clinical or clinicogenetic-risk models in patients with symptomatic FL who received frontline immunochemotherapy. Of 191 patients with FL grades 1 to 3a, 109 were successfully genotyped. The treatment consisted of rituximab (R) plus cyclophosphamide, vincristine, and prednisone (R-CVP)/cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (72.5%) or R-bendamustine (R-B) (27.5%). The proportion of cases classified as high risk for FLIPI, FLIPI-2, PRIMA–prognostic index, or m7-FLIPI were 39.3%, 14%, 30.3%, and 22%, respectively. No case with low-intermediate FLIPI was upgraded in the m7-FLIPI, but 18 of the 42 high-risk patients with FLIPI were downgraded to low-risk m7-FLIPI. The sensitivity and specificity for the prediction of POD24 were highest for FLIPI. The discrimination between progression-free survival (PFS) and overall survival (OS) was the best for FLIPI (c-index: 0.644 and 0.727, respectively). When analyzed only in patients treated with R-B, m7-FLIPI showed a higher discrimination between PFS and OS. Thus, the FLIPI remains the clinical risk score with higher discrimination in patients with advanced FL treated with immunochemotherapy; however, the performance of the m7-FLIPI should be further investigated in patients treated with R-B. 2023-06-22T07:51:01Z 2023-06-22T07:51:01Z 2023-04-26 journal article Rodríguez-Sevilla, J. J., Fernández-Rodríguez, C., Bento, L., Diez-Feijóo, R., Pinzón, S., Gibert, J., ... & Salar, A. (2023). Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy. Blood Advances, 7(8), 1606-1614[https://doi.org/10.1182/bloodadvances.2022007949] https://hdl.handle.net/10481/82708 10.1182/bloodadvances.2022007949 eng http://creativecommons.org/licenses/by-nc-nd/4.0/ open access Attribution-NonCommercial-NoDerivatives 4.0 Internacional American Society of Hematology